This roundtable series gauges the use of combination CD19 inhibition and chemotherapy in the previously treated diffuse large B-cell lymphoma setting, as discussed by participants at virtual live events.
Considering Alternatives to CAR T-Cell Therapy for Primary Refractory DLBCL
June 20th 2022During a live virtual event, Jakub Svoboda, MD, discussed with participants the choice of therapy for a patient with relapsed/refractory diffuse large B-cell lymphoma who would not receive stem cell transplant or chimeric antigen receptor therapy.